Hashem Farrokh

Array ( [id] => 12260604 [patent_doc_number] => 20180079800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'Human Immunodeficiency Virus Neutralizing Antibodies and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/719738 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 34431 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15719738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435381 [patent_doc_number] => 20200031874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => ZIKA VIRUS VACCINES [patent_app_type] => utility [patent_app_number] => 16/337363 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16548583 [patent_doc_number] => 10881722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Epizootic hemorrhagic disease vaccine [patent_app_type] => utility [patent_app_number] => 16/334885 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 15 [patent_no_of_words] => 10566 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16334885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16428302 [patent_doc_number] => 10828363 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-11-10 [patent_title] => Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates [patent_app_type] => utility [patent_app_number] => 15/705549 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 26 [patent_no_of_words] => 33379 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15705549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353106 [patent_doc_number] => 10793607 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Trimer stabilizing HIV envelope protein mutations [patent_app_type] => utility [patent_app_number] => 15/704651 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 38 [patent_no_of_words] => 31384 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12238537 [patent_doc_number] => 20180071400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'IMMUNOGENIC POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/695753 [patent_app_country] => US [patent_app_date] => 2017-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 37115 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15695753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17619006 [patent_doc_number] => 11338033 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-24 [patent_title] => Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof [patent_app_type] => utility [patent_app_number] => 16/329592 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 130 [patent_no_of_words] => 32706 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702755 [patent_doc_number] => 20170362332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE [patent_app_type] => utility [patent_app_number] => 15/676296 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15676296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15814067 [patent_doc_number] => 10632190 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => Compositions, methods and kits for eliciting an immune response [patent_app_type] => utility [patent_app_number] => 15/676330 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 62 [patent_no_of_words] => 29781 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15676330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051453 [patent_doc_number] => 20170327797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'RECOMBINANT HBV CCCDNA, THE METHOD TO GENERATE THEREOF AND THE USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/661283 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 13592 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898463 [patent_doc_number] => 20200148750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => Ebola Virus Antibodies and Binding Agents Derived Therefrom [patent_app_type] => utility [patent_app_number] => 16/319775 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21288 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16319775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030819 [patent_doc_number] => 20170320918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM' [patent_app_type] => utility [patent_app_number] => 15/655825 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10669 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15655825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15994109 [patent_doc_number] => 20200172925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => COMPOSITIONS AND METHODS FOR ALPHAVIRUS VACCINATION [patent_app_type] => utility [patent_app_number] => 16/317747 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648802 [patent_doc_number] => 10925956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Methods and compositions for inducing protective immunity against a marburg virus infection [patent_app_type] => utility [patent_app_number] => 16/317111 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17013 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12791581 [patent_doc_number] => 20180155696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => METHODS AND COMPOSITIONS RELATING TO VIRAL LATENCY [patent_app_type] => utility [patent_app_number] => 15/645505 [patent_app_country] => US [patent_app_date] => 2017-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15645505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16413308 [patent_doc_number] => 10821170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Duck Enteritis Virus and the uses thereof [patent_app_type] => utility [patent_app_number] => 16/313174 [patent_app_country] => US [patent_app_date] => 2017-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 13012 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16313174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14700669 [patent_doc_number] => 10378069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Compositions and methods for detecting zika virus [patent_app_type] => utility [patent_app_number] => 15/633449 [patent_app_country] => US [patent_app_date] => 2017-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11271 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15633449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17266371 [patent_doc_number] => 11191775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection [patent_app_type] => utility [patent_app_number] => 16/310765 [patent_app_country] => US [patent_app_date] => 2017-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 22940 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18232143 [patent_doc_number] => 11596687 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens [patent_app_type] => utility [patent_app_number] => 16/309297 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19716 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16309297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467811 [patent_doc_number] => 20190185548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => ANTIVIRAL POLYCLONAL ANTIBODIES AGAINST EBOLA VIRUS AND THE USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/307951 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307951 [rel_patent_id] =>[rel_patent_doc_number] =>)